Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
Yu Jing,1,* Xue Shen,2,* Qian Mei,3 Weidong Han3 1Department of Hematology, PLA General Hospital, 2Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, 3Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beij...
Main Authors: | Jing Y, Shen X, Mei Q, Han W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-10-01
|
Series: | OncoTargets and Therapy |
Online Access: | https://www.dovepress.com/spotlight-on-decitabine-for-myelodysplastic-syndromes-in-chinese-patie-peer-reviewed-article-OTT |
Similar Items
-
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
by: Taichun Qin, et al.
Published: (2011-01-01) -
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
by: Xiao Li, et al.
Published: (2014-01-01) -
Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes
by: V N Dvirnyk, et al.
Published: (2013-07-01) -
Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
by: Ye X, et al.
Published: (2017-11-01) -
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
by: Jacqueline S Garcia, et al.
Published: (2010-02-01)